Última actualización 22 de julio de 2026
Key finding
17.5% of patients showed a reduction from grade 3 to grade 1 on MRI.
This study examined the effects of Empagliflozin on liver health in patients with Type 2 Diabetes Mellitus, finding significant improvements in liver fat and liver enzyme levels.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Medium-Term (3–12 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study examined the effects of Empagliflozin on liver health in patients with Type 2 Diabetes Mellitus, finding significant improvements in liver fat and liver enzyme levels.
Improving liver health in patients with Type 2 Diabetes Mellitus is crucial, as liver complications can lead to serious health issues. The findings suggest that Empagliflozin not only aids in managing diabetes but also supports liver function, potentially reducing the risk of liver-related complications.
The study's effectiveness data were unclear for some outcomes. Sample size and demographic details were not specified. Results may not be generalizable to all populations with Type 2 Diabetes Mellitus.
Published in
Publication details and source links for this paper.
Fatemeh S, Azam E, Saeid K, Shahriar N, Latif G. The effects of Empagliflozin on liver health in patients with Type 2 Diabetes Mellitus (T2DM). BMC Endocrine Disorders. 2025;25:52. doi:10.1186/s12902-025-01882-8
17.5% of patients showed a reduction in liver fat grade from grade 3 to grade 1.
ALT abnormalities had a relative risk of 0.72 (95% CI: 0.62–0.84), indicating a decrease.
AST and alkaline phosphatase abnormalities were significantly lower in the intervention group.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Empagliflozin and AST, Alanine Aminotransferase (ALT), Reduction in liver fat grade from MRI assessments, and 2 more.
This study contributes evidence to
Primary intervention
Empagliflozin
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
5
Evidence pairs
29
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Relación de evidencia
Evidencia relacionada
Relación de evidencia
Guardar evidencia
Tema de evidencia
Guardar evidencia
Core evidence
The primary outcomes reported in this study.
Empagliflozin → Alanine Aminotransferase (ALT)
Empagliflozin → Alanine Aminotransferase (ALT)
Empagliflozin → Reduction in liver fat grade from MRI assessments
Empagliflozin → Reduction in liver fat grade from MRI assessments
Empagliflozin → Risk of alkaline phosphatase abnormalities after treatment
Empagliflozin → Risk of alkaline phosphatase abnormalities after treatment
Empagliflozin → Systolic blood pressure
Empagliflozin → Systolic blood pressure
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on SGLT2 Inhibitors and Adipokine and Angiogenic Markers, SGLT2 Inhibitors and Risk of alkaline phosphatase abnormalities after treatment.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring Adipokine and Angiogenic Markers
Measures Adipokine and Angiogenic Markers as a key outcome.
All studies on SGLT2 Inhibitors
Contributes to SGLT2 Inhibitors evidence base.
All studies measuring Blood Pressure
Measures Blood Pressure as a key outcome.
All studies measuring Risk of alkaline phosphatase abnormalities after treatment
Measures Risk of alkaline phosphatase abnormalities after treatment as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
2 results
1 results
2 results
2 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
SGLT2 Inhibitors may improve Adipokine and Angiogenic Markers.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Alanine Aminotransferase (ALT)
EvidenceScore™ Moderate | EvidenceScore™ 69.0 | strong positive | ConsistencyScore™ Consistent | 1 study
Why this answer: This answer is based on 7 supporting studies with consistent results and a positive effect signal.
Limitations
SGLT2 Inhibitors may improve Blood Pressure.
ConsistencyScore™: Results are consistent across studies.
Ranked evidence signals
Systolic blood pressure
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on 5 supporting studies with consistent results and a positive effect signal.
Limitations
Empagliflozin appears to improve AST.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
AST
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Empagliflozin appears to improve Reduction in liver fat grade from MRI assessments.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Reduction in liver fat grade from MRI assessments
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | strong positive | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Centrada en la evidencia, no en la publicidad.
Tus datos siempre están protegidos.
Se agregan nuevos estudios todos los días.
